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Elevated hippocampal activation is observed in con-
ditions that confer risk for Alzheimer’s disease, in-
cluding amnestic mild cognitive impairment (aMCI).
Studies in relevant animal models have indicated
that overactivity in selective hippocampal circuits
contributes to cognitive impairment. Here, we tested
the effect of reducing hippocampal activation in
aMCI. Under placebo treatment, hippocampal acti-
vation in the dentate gyrus/CA3 was elevated in
aMCI patients compared to a healthy control group.
By using a low dose of the antiepileptic levetiracetam
hippocampal activation in aMCI was reduced to a
level that did not differ from the control group. Com-
pared to aMCI memory performance under placebo,
performance in the scanning task was significantly
improved under drug treatment. Contrary to the
view that greater hippocampal activationmight serve
a beneficial function, these results support the view
that increased hippocampal activation in aMCI is
a dysfunctional condition and that targeting excess
hippocampal activity has therapeutic potential.
INTRODUCTION
In studies using functional magnetic resonance imaging (fMRI),
elevated hippocampal activation is observed in a number of
conditions that confer risk for Alzheimer’s disease (AD), including
cognitively normal carriers of theApoE4 allele (Bookheimer et al.,
2000; Trivedi et al., 2008; Filippini et al., 2009; Dennis et al.,
2010), presymptomatic carriers of genetic mutations for familial
AD (Quiroz et al., 2010), and patients with amnestic mild cogni-
tive impairment (aMCI) (Dickerson et al., 2004, 2005; Celone
et al., 2006; Ha¨ma¨la¨inen et al., 2007), although patients with
late aMCI and early AD show reduced hippocampal activity
(Celone et al., 2006; for a review see Ewers et al., 2011). In the
case of early aMCI, a condition in which memory is worse thanwould be expected for a person’s age, such increased hippo-
campal activation has been suggested to serve a beneficial
compensatory function by recruiting additional neural resources.
An alternative view is that excess activation directly contributes
to memory impairment and may be tied to widespread degener-
ative processes in prodromal AD (Putcha et al., 2011).
Supporting the possibility of adverse consequences, studies
in a rodent model of age-related memory loss have demon-
strated that abnormally elevated neural activity specifically
occurs in the CA3 region of the hippocampus when those neu-
rons are unable to encode new information (Wilson et al., 2005,
2006). Additionally, treatments designed to target excess CA3
activity in that animal model, including the use of low doses
of certain antiepileptic drugs (AED), were demonstrated to
improve memory performance (Koh et al., 2010). Consistent
with those findings, recent evidence from high-resolution fMRI
in humans indicates that greater hippocampal activation in
aMCI localizes to the dentate gyrus/CA3 (DG/CA3) region (Yassa
et al., 2010), suggesting similar network dysfunction. Together,
these findings support the concept that reducing excess activity
would have potential benefit in aMCI. The current study tested
that hypothesis using a FDA approved compound to lower
excess hippocampal activity.RESULTS
Here, we used low-dose levetiracetam, an AED that has shown
efficacy in animals with hippocampal hyperactivity (Koh et al.,
2010), to examine the functional significance of this condition
in aMCI. Seventeen patients with aMCI and seventeen healthy
age-matched control subjects completed a baseline assess-
ment after which they participated in two treatment phases,
separated by a washout period of 4 weeks. Control subjects
were given placebo during both treatment phases (single-blind)
while patients with aMCI were given placebo during one treat-
ment phase and low-dose levetiracetam (125 mg BID) during
the second treatment phase, with order of treatment counterbal-
anced (randomized, double-blind). After 2 weeks in each treat-
ment phase, participants completed a high-resolution fMRI
scan while performing a cognitive task designed to assessNeuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc. 467
Table 1. Demographics and Clinical Characterization of Healthy
Controls and aMCI Patients
Characteristic
Controls MCI
p ValueMean SD Mean SD
Subjects 17 17 –
Sex (M/F) 9/8 6/11 0.307
Age (years) 69.4 7.0 72.9 8.9 0.201
Education (years) 15.9 2.6 15.8 2.9 0.951
CDR 0 0.5 –
MMSE 27.9 1.5 25.7 2.3 0.002
BSRT Delayed Recall 7.7 1.9 3.6 2.4 <0.001
Wechsler VPA
Delayed Recall
7.0 1.5 3.9 2.9 <0.001
BVRT 5.8 1.8 4.5 1.5 0.026
CDR, Clinical Dementia Rating; MMSE, Mini Mental Status Exam; BSRT,
Buschke Selective Reminding Test; VPA, Verbal Paired Associates;
BVRT, Benton Visual Retention Test. See also Table S1.
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2010; Toner et al., 2009; Stark et al., 2010). It was hypothesized
that if hippocampal hyperactivity serves a compensatory role,
reducing that activity would further degrade memory function.
However, if the observed hyperactivity is a condition contributing
to hippocampal dysfunction, reducing excess activity should
improve memory performance in those patients. Here, we
show that greater hippocampal activation in aMCI relative to
the control group was isolated to the DG/CA3 region consistent
with earlier studies. Treatment with low-dose levetiracetam
significantly reduced that excess activity, such that hippocampal
activation in patients on drug did not differ from age-matched
control subjects. Additionally, drug treatment significantly im-
proved three-choice recognition performance. Memory errors
attributable to DG/CA3 dysfunction, which differed between
the groups when aMCI subjects were on placebo, were signifi-
cantly reduced by levetiracetam treatment.
Diagnosis of aMCI was based on criteria proposed by
Petersen et al. (1999). Patients with aMCI had a global clinical
dementia rating (CDR; Morris, 1993) of 0.5 with a sum of boxes
score not exceeding 2.5, scored at least 1.5 standard deviations
below the norm on neuropsychological assessments of memory
function, and reported a decline of memory confirmed by an
informant. These aMCI subjects showed impairments in both
single and multiple domains (All neuropsychological test data
acquired at baseline are shown in Table S1, available online).
Healthy control subjects had a global CDR of 0 and scoredwithin
1 standard deviation of the norm on neuropsychological testing.
Group demographics and baseline data are shown in Table 1.
At the end of each treatment phase, participants completed
a high-resolution fMRI scan while performing a memory task
designed to assess the function of the DG/CA3 network (Bakker
et al., 2008; Lacy et al., 2011). Subjects were presented with
a series of pictures of everyday objects and asked to determine
for each object if the item was ‘‘new,’’ ‘‘old,’’ or ‘‘similar.’’ As in
typical 2-judgment recognition memory tests, an item was cor-
rectly judged ‘‘new’’ if it was seen for the first time in the context
of the task and ‘‘old’’ if the item was repeated. The third option of468 Neuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc.‘‘similar’’ was the correct judgment when an object only resem-
bled an item previously seen in the task (Figure 1A). These
‘‘similar lures’’ were the critical trials for assessment of DG/
CA3 contribution to memory performance. Correct identification
of ‘‘similar’’ items should depend on DG-mediated pattern sepa-
ration, referring to the ability to encode inputs with some degree
of overlapping information into distinctive representations. The
CA3 and its strong autoassociative network mediates a com-
plementary function of pattern completion, in which retrieval
of previously stored information is based on commonalities
between current input and prior experience (Figure 1B). These
functions of the DG/CA3 network are supported by behavioral
and neurophysiological data obtained in animal studies (Leutgeb
et al., 2004; Leutgeb and Leutgeb, 2007; McHugh et al., 2007),
which have also shown a weakening of pattern separation and
a shift to pattern completion in age-related memory loss when
CA3 neurons are hyperactive (Wilson et al., 2003, 2005, 2006).
Consistent with those findings, behavioral data obtained in
three-choice recognition memory tasks from elderly humans
show a shift in performance toward pattern completion, as re-
flected during lure trials by more incorrect ‘‘old’’ responses and
fewer correct ‘‘similar’’ responses when compared to young
adults (Toner et al., 2009; Stark et al., 2010). This error profile
on lure trials is further worsened in aMCI patients compared to
normal aging (Yassa et al., 2010).
Functional neuroimaging data was first subjected to a one-
way analysis of variance (ANOVA) of trial type to select voxels
that showed task related activity (see Experimental Procedures).
To avoid selection bias while acknowledging the dependence of
observations in the two treatment conditions for aMCI subjects,
this analysis included data from all control subjects and aMCI
patients randomly selected from either their placebo or their
drug condition such that both treatment conditions were equally
represented (approximately half from placebo and half from the
drug condition). This analysis maintains independence of obser-
vations by including each aMCI patient only once. Unrelated foil
items correctly identified as ‘‘new’’ were used as an implicit
baseline against which all other conditions were compared.
This analysis resulted in an area of task-related activity
localized within the left DG/CA3 subregion of the hippocampus
(Figure 2C).
Increased DG/CA3 Activation in aMCI Compared
to Age-Matched Controls
To assess whether increased hippocampal activation was
observed in the current study of patients with aMCI, we first
compared functional activity during fMRI memory task perfor-
mance between healthy control subjects and patients with
aMCIonplacebowithin theDG/CA3 regionasshown inFigure2C.
The aMCI patients on placebo showed significantly increased
blood oxygenation level-dependent (BOLD) activation during
lure trials correctly identified as similar when compared to control
subjects (t = 2.056, p = 0.048) (Figure 2E; see also Figure S1). This
finding replicates earlier findings in Yassa et al. (2010).
Behavioral performance of the aMCI subjects on placebo
compared to healthy controls during the scanning task was as-
sessed by the rates of each response option (old, similar, or
new) on the critical lure trials. A between-groups ANOVA using
Figure 1. Task Designed to Tax Hippocampal DG/CA3 Function
(A) Participants were presented with pictures of everyday objects for 2,500 ms each separated by a 500 ms interstimulus interval and asked to judge if the item
was new (seen for the first time), old (a repeated item), or similar (resembled a previously shown item). The similar lure items served as the critical trials for
assessing performance dependent on the dentate gyrus/CA3. (B) The entorhinal cortex (EC) provides input from the cortex, via layer II (EC2) neurons, to the
dentate gyrus (DG) and distal dendrites of CA3 pyramidal neurons. The CA3 afferents, in addition to innervating CA1, have autoassociative collaterals, forming the
majority of CA3 synaptic input. The EC2 neurons and their targets in the hippocampus comprise a system that rapidly encodes representations that are distinct
from prior memories. The sparse connections onto granule cells in DG by EC afferents promote pattern separation, while the recurrent CA3 network promotes
pattern completion (adapted with permission from Gallagher and Koh, 2011).
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response independence revealed a significant effect of response
type (F(1,32) = 5.357, p = 0.027) and, importantly, a significant
group (control versus aMCI placebo) 3 response interaction
(F(1,32) = 7.687, p = 0.009) showing that aMCI patients on placebo
incorrectly identified lure itemsas ‘‘old’’moreoftenandgave rela-
tively fewer correct responses of ‘‘similar’’ compared to control
subjects (Figure 3A). That profile is consistent with reduced
pattern separation and a shift to pattern completion in aMCI.
Furthermore, a correlational analysis of activity in the left DG/
CA3 and the proportion of lures called similar showed a marginal
inverse relationship in patients with aMCI such that increasedactivity in the DG/CA3 was associated with fewer correct
responses of ‘‘similar’’ to lure items reflecting reduced pattern
separation (r = 0.433, p = 0.083; Figure S1). In contrast, such
a correlation was not observed in control subjects.
Together, these results demonstrate that patients with aMCI
had increased activation in the left DG/CA3 subregion of the
hippocampus and performed significantly worse on trials with
lures, compared to the age-matched control group. These
results are consistent with earlier reported findings (Yassa
et al., 2010), providing a sample of aMCI patients appro-
priate for testing the functional significance of hippocampal
hyperactivity.Neuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc. 469
Figure 2. Levetiracetam Treatment Normalizes Increased Dentate Gyrus/CA3 Activity in Patients with aMCI
(A) High-resolution anatomical scan, with the left medial temporal lobe demarcated. (B) Segmentation of medial temporal lobe structures, including the CA1,
dentate gyrus/CA3 (DG/CA3) and subiculum (SUB) subregions of the hippocampal formation. The boundaries between the CA3 and dentate gyrus (DG) cannot be
clearly defined in structural scans and, therefore, are combined as DG/CA3 for analysis. (C) Area of task related activity based on an ANOVA of task condition in
the left DG/CA3. (D) Area of task related activity in the left DG/CA3 resulting from the confirmatory analysis in which voxel selection is based on ANOVA of task
condition that includes only age-matched healthy control subjects. (E) Graphs showmean activity ± SEM on lure trials correctly called similar. Patients with aMCI
on placebo show increased activity in the left DG/CA3 compared to healthy control subjects during the lure trials. (F) Levetiracetam treatment significantly
reduced activity in the DG/CA3 in patients with aMCI compared to the placebo condition. (G) In the confirmatory analysis for drug treatment, patients with aMCI
taking low dose levetiracetam again showed significantly reduced BOLD activation during lure trials correctly identified as similar relative to the activity during
those trials under placebo treatment. *p < 0.05 group comparisons using independent and paired samples t tests respectively. See also Figure S1.
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Improves Memory Function in the Three-Choice
Memory Task
To assess whether low dose levetiracetam treatment reduces
the observed increased DG/CA3 activation, we compared func-
tional data during the fMRI memory task in aMCI patients upon
completion of the placebo and drug treatment phases. Within
the neuroanatomical region of task related activity (as shown in
Figure 2C), low-dose levetiracetam significantly reduced BOLD
activation relative to the placebo treatment (t = 2.537, p =
0.022; Figure 2F). This effect was not influenced by order of treat-
ment. Thus there was no evidence for any carryover 6 weeks
after drug treatment was terminated (4 week washout and
placebo for 2 weeks before the second assessment). Further,
BOLD activation in the DG/CA3 in aMCI patients after levetirace-
tam treatment did not differ from activity in that region observed
in the normal age-matched control subjects. To confirm this
finding, a separate analysis was conducted in which voxel selec-
tion was based on a one-way ANOVA of trial type only in control
subjects. This analysis resulted in an area of task related activity
similarly localized in the left DG/CA3 subregion of the hippo-
campus (Figure 2D). The effect of drug treatment was confirmed470 Neuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc.by comparing fMRI activation in that area of task related activity
in aMCI patients on placebo and levetiracetam. In that analysis,
patients with aMCI taking low dose levetiracetam again showed
significantly reduced BOLD activation relative to their activity
under placebo treatment (t = 2.192, p = 0.044; Figure 2G). These
effects were obtained with a drug dose well below that used clin-
ically for the treatment of epilepsy; drug levels in patients were
determined to be 4.4 mcg/ml ± 0.53 (mean and SEM), as
compared to typical ranges for efficacy as an antiepileptic
with doses of 1,000–3,000 mg/day achieving levels of 10–
40 mcg/ml (Lyseng-Williamson, 2011).
Treatment with low dose levetiracetam also improved behav-
ioral performance on the lure trials. Analysis of the responses on
those trials showed an overall significant effect of response type
(F(1,16) = 5.992, p = 0.026), and, importantly, a significant interac-
tion effect of treatment (drug versus placebo) 3 response
(F(1,16) = 5.028, p = 0.039) showing that relative to their perfor-
mance on placebo, aMCI patients taking levetiracetam made
fewer incorrect responses of ‘‘old’’ while concomitantly in-
creasing correct judgments of ‘‘similar’’ (Figure 3B).
Finally, in addition to the fMRI scanning session, partici-
pants completed a neuropsychological assessment after each
Figure 3. Levetiracetam Treatment Improves Task-Related Memory Performance on Critical Lure Items in Patients with aMCI
(A) Patients with aMCI on placebo had impairedmemory performance bymore often incorrectly judging lure items as ‘‘old’’ instead of ‘‘similar’’ when compared to
healthy control subjects. (B) Levetiracetam improved performance in aMCI patients, by reducing errors in which lures were incorrectly judged ‘‘old,’’ with more
correct judgments of ‘‘similar,’’ when comparing aMCI performance on drug with placebo. *Two-way repeated-measures ANOVA revealed a significant contrast
for the interaction of group as a function of response type (old versus similar), p < 0.05. Values are means ± SEM. See also Figure S2.
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mance as assessed by neuropsychological tests of memory or
general cognitive functioning. Specifically within the memory
domain, performance of patients with aMCI after taking levetira-
cetam for 2 weeks did not differ significantly compared to their
performance on placebo for delayed recall on the Buschke
Selective Reminding Test (Buschke and Fuld, 1974) (t = 0.145,
p = 0.887), delayed recall on the Verbal Paired Associates
subtest of the Wechsler Memory Scale (Wechsler, 1997) (t =
0.194, p = 0.848) and the Benton Visual Retention Test (Benton,
1974) (t = 0.251, p = 0.805), while performance of aMCI partici-
pants under both treatment conditions differed from the age-
matched control group (p < 0.05; see Figure S2).
DISCUSSION
The functional significance of greater hippocampal activation in
aMCI is addressed by the current study, which fails to support
the view that such activity benefits memory performance. After
levetiracetam treatment, when DG/CA3 activation was reduced
in aMCI patients, no worsening of memory occurred either in
the scanning task or on memory tests in a neuropsychological
assessment. To the contrary, levetiracetam treatment altered
performance in the three-choice memory task in a manner
consistent with improved DG/CA3 function, indicating the thera-
peutic potential of targeting excess hippocampal activation
in aMCI.
The lure items in the memory task are designed to assess the
balance of pattern separation and pattern completion mediated
by the DG/CA3. In memory-impaired aged rats with excess CA3
activity, the CA3 pyramidal neurons activate representations tied
to prior experiences and fail to encode distinctive representa-
tions for new information, indicating a shift in network function
toward greater pattern completion and diminished pattern sepa-
ration (Wilson et al., 2006). A similar condition in humans wouldbe expected to produce more errors with lures incorrectly iden-
tified as repetitions of prior items rather than correctly identified
as similar but distinctive, only sharing features with prior items in
the task. We found this specific profile in the aMCI patients.
Furthermore, comparing aMCI patients on placebo with drug
treatment demonstrated that a low dose of levetiracetam, which
attenuated DG/CA3 activation, significantly improved perfor-
mance by reducing errors attributable to an overriding pattern
completion process. To the extent that excess hippocampal
activation does not serve a supportive memory function, such
activity might not only contribute to memory impairment but
also have adverse effects on vulnerable neural systems.
The current findings may have broader implications because
increased hippocampal activation occurs not only in aMCI, but
also in other conditions associated with risk for AD.Many studies
of ApoE4 carriers have reported increased fMRI activation in the
hippocampus (Dickerson et al., 2004, 2005; Celone et al., 2006;
Ha¨ma¨la¨inen et al., 2007). Contrary to the notion that such activity
is compensatory, recent research has revealed a loss of hippo-
campal inhibitory function in animal models used to study
ApoE4, and demonstrated that such loss contributes to behav-
ioral deficits (Andrews-Zwilling et al., 2010). In those models of
ApoE4, memory performance was improved by treatment with
the GABAA receptor potentiator, pentobarbital. In the context
of the hippocampal subsystem highlighted here, it is also note-
worthy that the impact of ApoE4 on inhibitory circuits in mouse
models was regionally restricted within the hippocampal forma-
tion, affecting interneurons in the hilus but not in CA1. Greater
hippocampal activation is also a signature in genetic conditions
for familial AD (Quiroz et al., 2010), and aberrant excitatory
activity affecting hippocampal circuits occurs in mouse models
of familial AD (Palop et al., 2007).
Apart from contributing to symptomatic memory impairment,
there is concern that elevated activity in vulnerable neural
networks could drive pathophysiology in conditions of risk forNeuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc. 471
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that elevated hippocampal activation may be tied to widespread
disease related degeneration in a distributed network of brain
regions in prodromal AD (Putcha et al., 2011) and predicts
subsequent cognitive decline and conversion to AD (Dickerson
et al., 2004; Miller et al., 2008; O’Brien et al., 2010). Mechanisms
tied to AD amyloid pathology demonstrate that fluctuations in
neural activity dynamically regulate levels of Ab in the interstitial
fluid (Bero et al., 2011). Such findings support the regulation of
neural activity as a possible therapeutic modality to modify
disease progression. The current findings encourage such an
approach, indicating that patients receiving levetiracetam did
not lose function that might have been supported by greater
recruitment of neural activity but instead exhibited a benefit as
predicted by computational models and preclinical studies of
animals with age-related memory loss.
EXPERIMENTAL PROCEDURES
Participants and Clinical Characterization
Twenty-three patients with amnestic mild cognitive impairment (aMCI) and 22
healthy older adults participated. Complete data from 17 aMCI patients and 17
control participants were included in the analysis. Data from 6 aMCI patients
and 5 control participants were excluded from analysis due to inability to
complete the MRI session, not taking the study medication according to the
instructions provided or were otherwise unable to complete the study protocol.
See Table 1 with additional details in Supplemental Experimental Procedures.
All participants underwent medical, psychiatric, neurological and neuropsy-
chological evaluations, which included the Buschke Selective Reminding Test
(Buschke and Fuld, 1974), the Verbal Paired Associates subtest of the Wechs-
lerMemory Scale (Wechsler, 1997), and theBenton Visual Retention Test (Ben-
ton, 1974) and completed the Clinical Dementia Rating Scale (Morris, 1993). All
aMCI patients had global CDR scores of 0.5 with a sum of boxes score not
exceeding 2.5 and met the diagnostic criteria for aMCI proposed by Petersen
et al. (1999). All healthy control subjects had a global CDR score of 0. None of
the aMCI patients or healthy control participants met criteria for dementia.
Study Design
All participants completed a total of four study visits. Participants in the healthy
control group were assigned to placebo in both treatment phases. If a partici-
pant met criteria for the aMCI group, the participant was randomly assigned to
either the placebo condition or the levetiracetam condition. Participants were
provided with the study medication (either placebo or drug) and provided with
instructions to take one capsule twice daily until the next visit. The second visit
occurred approximately 2 weeks after the first visit and included a brief
medical and psychiatric exam, a blood draw, and a MRI. The third visit
occurred approximately 4 weeks after the second visit and included a brief
medical and psychiatric exam and a blood draw. No treatment occurred
between the second and the third visit. At the third visit, the participant was
provided with study medication for the second treatment phase of the study.
A counterbalanced design was used such that aMCI patients who received
placebo for the first treatment phase received levetiracetam and aMCI patients
who received levetiracetam for the first treatment phase received placebo for
the second treatment phase of the study. The fourth and final visit occurred
approximately 2 weeks after the third and was identical to the second visit.
All participants were blind to their treatment status throughout the study.
The study team was blind to the treatment status of the aMCI patients and lev-
etiracetam blood levels until the completion of the study. The study protocol
was approved by the Institutional Review Board of the Johns Hopkins Medical
Institutions (for additional details see Supplemental Experimental Procedures).
fMRI Acquisition
The fMRI behavioral paradigm was a three-alternative forced choice task
described in detail previously (Yassa et al., 2010; Lacy et al., 2011). High-472 Neuron 74, 467–474, May 10, 2012 ª2012 Elsevier Inc.resolution functional images were collected on a 3 Tesla Phillips scanner using
a T2*-weighted echo planar single shot pulse sequence with an acquisition
matrix of 64 3 64, an echo time of 30 ms, flip angle of 70, a SENSE factor of
2, an in plane resolution of 1.5 3 1.5 mm, and a TR of 1.5 s (Kirwan et al.,
2007). Each volume consisted of 19 oblique 1.5 mm thick axial slices with no
gaporientedalong theprincipal axis of thehippocampusandcovered themedial
temporal lobe bilaterally. Each run consisted of 96 trials and each trial was pre-
sented for2,500mswitha500ms interstimulus interval. Eachsubject completed
8 runs. In addition, a whole brain structural scan was acquired using a magneti-
zationprepared rapidgradient echo (MP-RAGE)T1-weightedsequencewith231
oblique slices, 0.65 mm isotropic resolution, and a field of view of 240.
Image data analysis was performed using the Analysis of Functional Neuro-
images software package (Cox, 1996). The resulting statistical fit coefficient
maps represent the difference in activity between each of the task trial types
and the baseline for a given time point for a given voxel. The statistical maps
were then smoothed using a Gaussian kernel of 3 mm to account for variations
in individual functional anatomy.Methods used for cross-participant alignment
in this studywere previously described in detail (Kirwan and Stark, 2007; Yassa
and Stark, 2009; Lacy et al., 2011). This method increases the power of multi-
subject regional fMRI studies by focusing the alignment power to the regions of
interest using a segmentation of the subject’s anatomical image. The resulting
3D vector field for each individual was then applied to the concatenated fit
coefficient maps resulting from the functional analysis (for additional details
see Supplemental Experimental Procedures).
Statistical Analysis
Age, education, and neuropsychological and functional assessment scores
between groups were compared using independent samples t tests. The
distribution of sex between groups was compared using a chi-square test.
The fMRI data was analyzed using a two-step procedure. First, a one-way
ANOVA of trial type (sTH, sLS, sLO, TH, LS, and LO) was used to select voxels
that showed task-related activity. All control and aMCI participants were
included in this analysis to avoid bias; however, to avoid thedependence arising
from the aMCI patients contributing two data points, aMCI data were randomly
selected fromeither theplaceboordrugcondition (approximately half fromeach
condition). In a confirmatory analysis, voxel selection was based on a one-way
ANOVA of trial type using only the healthy age-matched control subjects. The
second level statistical analysis for group and treatment differences used a final
alpha of .05 for tests in both themain analysis (between group and within-aMCI
for treatment condition) and in the confirmatory analysis of the aMCI data.
In the first level analysis, a voxel threshold of p < 0.07was used on the overall
F-statistic in combination with a spatial extent threshold of 40 voxels to select
areas of task related activation. Voxel selection based on trial type alone was
not robust at p = 0.05 due to increased variability introduced by collapsing
across groups. The voxel threshold at p < 0.07 yielded a sizable ROI for the
purpose of hypothesis testing in the main second level statistical analysis
and the confirmatory analysis. The resulting areas of activation in voxel selec-
tion were combined with the anatomical segmentations to only include voxels
within our areas of interest. This hybrid functional/anatomical analysis resulted
in clusters of voxels that showed changes with task condition within an
anatomical region of interest. In the main analysis, voxels within each func-
tional/anatomical region of interest were then collapsed for the second level
ROI analysis comparing control subjects and aMCI patients on placebo using
a t test. A separate paired samples t test was used to compare the placebo
condition to the levetiracetam condition in aMCI patients for both the main
and confirmatory analysis.
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